Legend Biotech Prices $226M Public Offering of ADSs at $29.35
LEGN sits 81% above its 52-week low of $16.24.
Summary
Legend Biotech priced a $226 million public offering of ADSs at $29.35 per share, raising over $211 million in net proceeds to fund its operations and clinical pipeline.
Key Events · Financing and Capital Events · LEGN
-
Public Offering Priced
Legend Biotech priced an underwritten public offering of 7.7 million American Depositary Shares (ADSs) at $29.35 per ADS, aiming to raise approximately $211.6 million in net proceeds.
-
Significant Capital Raise
The offering represents over 4% of the company's market capitalization, providing substantial capital for general corporate purposes and to fund ongoing clinical development.
-
Underwriters' Over-Allotment Option
The company granted underwriters a 30-day option to purchase up to an additional 1.155 million ADSs, which could further increase the total proceeds.
-
Finalizes Prior Disclosure
This 6-K provides the full underwriting agreement and press release, finalizing the terms of an offering previously disclosed in preliminary and final prospectus supplements on June 17 and June 18, 2026.
Analysis · LEGN · Life Sciences
This filing details Legend Biotech's successful pricing of a significant public offering, securing over $211 million in net proceeds. While the offering is dilutive for existing shareholders, representing over 4% of the company's market capitalization, it provides crucial capital for a life sciences company with an active clinical pipeline. The pricing at a modest discount to recent trading, following a series of positive clinical data announcements, suggests the company is strategically strengthening its balance sheet to fund ongoing research, development, and commercialization efforts, extending its financial runway.
At the time of this filing, LEGN was trading at $29.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $16.24 to $45.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.